Public Employees Retirement Association of Colorado purchased a new stake in shares of Acceleron Pharma Inc (NASDAQ:XLRN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,246 shares of the biopharmaceutical company’s stock, valued at approximately $138,000.
Several other hedge funds have also made changes to their positions in the stock. Schwab Charles Investment Management Inc. lifted its stake in shares of Acceleron Pharma by 11.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 175,553 shares of the biopharmaceutical company’s stock valued at $7,451,000 after buying an additional 17,601 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Acceleron Pharma during the 3rd quarter valued at approximately $1,496,000. Iguana Healthcare Management LLC purchased a new stake in shares of Acceleron Pharma during the 3rd quarter valued at approximately $2,612,000. Point72 Asset Management L.P. purchased a new stake in shares of Acceleron Pharma during the 3rd quarter valued at approximately $2,721,000. Finally, Granahan Investment Management Inc. MA increased its holdings in Acceleron Pharma by 15.2% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock worth $8,102,000 after acquiring an additional 28,694 shares during the period. Institutional investors own 90.13% of the company’s stock.
XLRN has been the topic of a number of analyst reports. BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Thursday, February 15th. Credit Suisse Group set a $51.00 target price on shares of Acceleron Pharma and gave the stock a “buy” rating in a report on Tuesday, November 14th. HC Wainwright upped their target price on shares of Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Acceleron Pharma currently has an average rating of “Buy” and a consensus target price of $44.81.
Acceleron Pharma Inc (NASDAQ XLRN) opened at $42.55 on Wednesday. The company has a market cap of $1,920.00, a price-to-earnings ratio of -16.49 and a beta of 1.45. Acceleron Pharma Inc has a twelve month low of $24.37 and a twelve month high of $46.93.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/02/21/3246-shares-in-acceleron-pharma-inc-xlrn-purchased-by-public-employees-retirement-association-of-colorado.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.